• Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs.
• The agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before January 2035.
• The settlement secures extended U.S. market exclusivity for FIRDAPSE and removes a key legal overhang for Catalyst.

Catalyst Pharmaceuticals focuses on treatments for rare neurological diseases, with FIRDAPSE as its lead commercial product. In that context, the settlement with Hetero Labs matters because it directly addresses generic risk around the company’s core drug. For investors watching NasdaqCM:CPRX, the resolution gives clearer visibility on how long FIRDAPSE may remain the only approved version in the U.S.

With the litigation now resolved, attention is likely to remain on how Catalyst and its future owner Angelini Pharma manage this extended exclusivity period. Key questions for readers include how the company prioritizes reinvestment in its pipeline, potential new indications, and any additional products that could diversify revenue beyond FIRDAPSE over time.

Stay updated on the most important news stories for Catalyst Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Catalyst Pharmaceuticals.

The settlement with Hetero effectively locks in U.S. FIRDAPSE exclusivity until January 2035, which removes a key uncertainty around Catalyst’s largest product just as Angelini Pharma is preparing to acquire the company. For you as a shareholder, that combination matters because it ties a long-duration cash-flow asset to a cash takeover that has already been agreed at US$31.50 per share. The agreement also ends all remaining FIRDAPSE patent disputes, meaning Angelini is not stepping into open litigation risk on the core franchise. Compared with other rare-disease and neurology-focused groups such as BioMarin, UCB or Alexion within AstraZeneca, Catalyst now presents as a cleaner, single-asset anchored platform in the U.S., which can be attractive for a buyer looking to expand its rare-disease footprint. The trade off is that existing investors are now mainly exposed to deal-completion risk rather than to the long-run outcome of that extended exclusivity period.

How This Fits Into The Catalyst Pharmaceuticals Narrative

• The settlement supports the existing narrative that FIRDAPSE provides a durable rare-disease revenue base, by clarifying that generic competition from Hetero is off the table in the U.S. until 2035 if it receives approval.
• It challenges earlier concerns in the narrative about near to medium term patent risk around FIRDAPSE, because this specific litigation path has now been closed out through settlements with multiple generic filers.
• The Angelini acquisition context, and the shift from an independent growth story to an agreed cash sale, is not fully reflected in the narrative’s focus on long-term earnings expansion and capital allocation by Catalyst as a standalone company.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Catalyst Pharmaceuticals to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ The acquisition still depends on Catalyst stockholder approval, regulatory clearances and other conditions, so there is a risk the transaction with Angelini does not close on the expected timeline or on the current terms.
• ⚠️ The agreed US$31.50 per share cash price can limit further upside if no competing bids emerge, which may feel restrictive if you think the longer FIRDAPSE exclusivity could have supported a higher standalone valuation.
• 🎁 The settlement removes the immediate threat of Hetero launching a FIRDAPSE generic before 2035, which reduces legal overhang around Catalyst’s key product and provides clearer revenue visibility for the buyer.
• 🎁 Combining Catalyst’s rare-disease portfolio with Angelini’s broader brain-health focus and international reach could create product and geographic synergies that support the combined group’s positioning against peers like BioMarin and UCB.

What To Watch Going Forward

From here, keep an eye on formal filings of the Hetero settlement with U.S. regulators, any commentary from Catalyst or Angelini about how FIRDAPSE exclusivity factors into the merger rationale, and updates on regulatory and antitrust review for the acquisition. It is also worth tracking whether any shareholder groups challenge the deal terms or whether alternative proposals surface before the stockholder vote, given the defined cash price and the now-clarified patent outlook for FIRDAPSE.

To stay informed on how the latest news impacts the investment narrative for Catalyst Pharmaceuticals, visit the community page for Catalyst Pharmaceuticals to follow the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.